Evidence map›Paper›PMID 28592889›Full record

Trial reportLeukemia2018

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

J R Brown, P Hillmen, S O'Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam, S P Mulligan, U Jaeger, P M Barr and 20 more

Open access · hybridAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 1 synthesis or guideline pooled it, 235 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Article
  17. Article
  18. EJHaem · 2025
    Article
  19. Article
  20. Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2025
    Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 8 countries.

J R BrownDana-Farber Cancer Institute, Boston, MA, USA.
P HillmenSt James Institute of Oncology, Leeds, UK.
S O'BrienMD Anderson Cancer Center, Houston, TX, USA.
J C BarrientosHofstra Northwell School of Medicine, Hempstead, NY, USA.
N M ReddyVanderbilt-Ingram Cancer Center, Nashville, TN, USA.
S E CoutreStanford University School of Medicine, Stanford, CA, USA.
C S TamPeter MacCallum Cancer Centre and St Vincent's Hospital, Melbourne, Australia.
S P MulliganRoyal North Shore Hospital, Sydney, Australia.
U JaegerMedical University of Vienna, Vienna, Austria.
P M BarrUniversity of Rochester Cancer Center, Rochester, NY, USA.
R R FurmanWeill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
T J KippsUCSD Moores Cancer Center, San Diego, CA, USA.
F CymbalistaHôpital Avicenne, Paris, France.
P ThorntonBeaumont Hospital, Dublin, Ireland.
F Caligaris-CappioUniversita Vita-Salute San Raffaele, Milan, Italy.
J DelgadoHospital Clinic, Barcelona, Spain.ORCID 0000-0002-5157-4376
M MontilloNiguarda Cancer Center Niguarda Hospital, Milan, Italy.
S DeVosDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
C MorenoHospital de la Santa Creu Sant Pau, Barcelona, Spain.
J M PagelSwedish Cancer Institute, Seattle, WA, USA.
T MunirSt James Institute of Oncology, Leeds, UK.
J A BurgerMD Anderson Cancer Center, Houston, TX, USA.
D ChungPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
J LinPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
L GauPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
B ChangPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
G ColePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
E HsuPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
D F JamesPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
J C ByrdThe Ohio State University Medical Center, Columbus, OH, USA.
AbbVie (United States) · USSt James's University Hospital · GBThe University of Texas MD Anderson Cancer Center · USAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITBeaumont Hospital · IEDana-Farber Cancer Institute · USHofstra University · USHôpital Avicenne · FRHospital Clínic de Barcelona · ESHospital de Sant Pau · ESMedical University of Vienna · ATMoores Cancer CenterNewYork–Presbyterian Hospital · USPeter MacCallum Cancer Centre · AURoyal North Shore Hospital · AUStanford University · USThe Ohio State University Wexner Medical Center · USUniversity of California, Los Angeles · USUniversity of Rochester · USVanderbilt University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
Targeted Therapy for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · PI ROGERS, KERRY ANNE, WOYACH, JENNIFER A. · 2013 to 2025
$5.3M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA177292NCI NIH HHS R35 CA197734
6 · The paper itself

Abstract

In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these traditionally chemotherapy resistant high-risk genomic subgroups at a median follow-up of 19 months. Mutations were detected by Foundation One Heme Panel. Baseline mutations in the ibrutinib arm included TP53 (51%), SF3B1 (31%), NOTCH1 (28%), ATM (19%) and BIRC3 (14%). Median PFS was not reached, with 74% of patients randomized to ibrutinib alive and progression-free at 24 months. The improved efficacy of ibrutinib vs ofatumumab continues in all prognostic subgroups including del17p and del11q. No significant difference within the ibrutinib arm was observed for PFS across most genomic subtypes, although a subset carrying both TP53 mutation and del17p had reduced PFS compared with patients with neither abnormality. Reduced PFS or OS was not evident in patients with only del17p. PFS was significantly better for ibrutinib-treated patients in second-line vs later lines of therapy. The robust clinical activity of ibrutinib continues to show ongoing efficacy and acceptable safety consistent with prior reports, independent of various known high-risk mutations.

Indexed as

AdenineAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutationNeoplasm Recurrence, LocalAdenineAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsibrutinibofatumumabPiperidinesPyrazolesPyrimidinesTumor Suppressor Protein p53

Identifiers

PMID28592889
PMCPMC5770586
OpenAlexW2623762297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.